Cause-Specific Mortality and Prognostic Impact of Comorbidity in Japanese Patients With Chronic Lymphocytic Leukemia.

In the frontline setting, the use of BTKi did not reach statistical significance in treatment durability (Figure S4B ); however, the observed two cases of early treatment change within 2 years were both in‐class switching (i.e., ibrutinib to acalabrutinib): one due to an ibrutinib‐induced rash and the other due to physician's preference.

also in 111,027 other papers